Effect of hypofractionated palliative thoracic radiotherapy for ad-vanced non-small cell lung cancer
10.3969/j.issn.1000-8179.20131579
- VernacularTitle:进展期非小细胞肺癌短疗程大分割姑息放疗疗效分析
- Author:
Weishuai LIU
;
Lujun ZHAO
;
Zhiyan LIU
;
Bo LI
;
Zhiyong YUAN
;
Ping WANG
- Publication Type:Journal Article
- Keywords:
non-small-cell lung cancer;
radiotherapy;
hypofractionation;
palliative radiotherapy
- From:
Chinese Journal of Clinical Oncology
2013;(20):1240-1243
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect and toxicity of short-course and hypofractionated palliative thoracic radiotherapy (PTR) for advanced non-small cell lung cancer (NSCLC). Methods:A total of 25 patients with stageⅢB and stageⅣNSCLC, who underwent PTR from September 2010 to July 2006, were retrospectively analyzed. The PTR regime was 45 Gy in 15 fractions. Symptom relief, effect, and toxicity after completion of PTR were assessed. Survival was analyzed using the Kaplan-Meier method. Results:Except for one patient who completed only 36 Gy in 12 fractions, all other patients completed all plans. The thoracic symptoms of 18 patients were relieved. The response rates for the five main symptoms were:hemoptysis 87.5%(7/8), cough 70.6%(12/17), pain 73.3%(11/15), dyspnea 57.1%(8/14), and hoarseness 50%(1/2). The complete response and partial response after PTR was 28%, and no grade 3 or higher toxicities occurred. The median time of overall survival (OS) is 13 months (95%CI:6.6 months to 19.5 months), and one-year OS is 51.5%. According to the univariate analysis, KPS before PTR, the number of post-PTR was significantly related to the survival. Conclusion:For advanced NSCLC patients, the PTR regime given as 45 Gy in 15 fractions evidently relieved thoracic symptoms, improved OS, and shortened treatment time. Recent relevant adverse radiotherapy reactions are low, and more prospective clinical studies must be conducted.
